Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 373-379

  Sommerer, Claudia ^a   Zeier, Martin ^a   Czock, David ^b   Schnitzler, Paul ^b   Meuer, Stefan ^b   Giese, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Nuclear factor of activated T cells; Pharmacodynamics; Renal transplantation; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; VALGANCICLOVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARMACOGENETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; REAL-TIME POLYMERASE CHAIN REACTION; TACROLIMUS; VIREMIA; YOUNG ADULT;

EID: 80051802715     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318226dac7     Document Type: Article

References (27)

1. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 kidney transplant study group. Transplantation. 1997;63:977-983. (Pubitemid 27173021)
2. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910-1917.
3. Mahalati K, Kahan BD. Pharmacological surrogates of allograft outcome. Ann Transplant. 2000;5:14-23.
4. Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2008;66: 467-472.
5. Armendariz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005;27:431-434. (Pubitemid 41098816)
6. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentrationranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 kidney transplant group. Transplantation. 1996;62:900-905. (Pubitemid 26360348)
7. Op den Buijsch RA, van de Plas A, Stolk LM, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007;63:1039-1044. (Pubitemid 47561802)
8. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992;89:3686-3690.
9. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant. 2002;2:173-178. (Pubitemid 36306797)
10. Blanchet B, Hulin A, Duvoux C, et al. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem. 2003;312:1-6. (Pubitemid 36015960)
11. Kel A, Kel-Margoulis O, Babenko V, et al. Recognition of NFATp/AP-1 composite elements within genes induced upon the activation of immune cells. J Mol Biol. 1999;288:353-376. (Pubitemid 29221807)
12. Humar A, Snydman D; and the AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(suppl 4):S78-S86.
13. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779-795.
14. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004;77:339-344. (Pubitemid 38209728)
15. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant. 2004;19(suppl 4):iv55-iv60. (Pubitemid 39136707)
16. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation. 2006;82:1280-1285. (Pubitemid 44832909)
17. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691. (Pubitemid 36459475)
18. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198. (Pubitemid 46871026)
19. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int. 2007; 20:1036-1043. (Pubitemid 350043847)
20. Sommerer C, Giese T, Schmidt J, et al. Cyclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008;85:15-21.
21. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49: 141-175.
22. Capron A, Mourad M, deMeyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010; 11:703-714.
23. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
24. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 2000;70:327-335. (Pubitemid 30602753)
25. Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001;23:354-362. (Pubitemid 32708918)
26. van den Berg AP, Twilhaar WN, van Son WJ, et al. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transpl Int. 1998;11(suppl 1):S318-S321. (Pubitemid 128683568)
27. Sommerer C, Zeier M, Meuer S, et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation. 2010;89:1417-1423.